|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar
|
|
2
|
Ma O, Cai WW, Zender L, Dayaram T, Shen J,
Herron AJ, Lowe SW, Man TK, Lau CC and Donehower LA: MMP13, Birc2
(cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate
with p53 deficiency in mouse osteosarcoma progression. Cancer Res.
69:2559–2567. 2009. View Article : Google Scholar
|
|
3
|
Sampson VB, Kamara DF and Kolb EA:
Xenograft and genetically engineered mouse model systems of
osteosarcoma and Ewing's sarcoma: Tumor models for cancer drug
discovery. Expert Opin Drug Discov. 8:1181–1189. 2013. View Article : Google Scholar
|
|
4
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar
|
|
5
|
Shi ZW, Wang JL, Zhao N, Guan Y and He W:
Single nucleotide polymorphism of hsa-miR-124a affects risk and
prognosis of osteosarcoma. Cancer Biomark. 17:249–257. 2016.
View Article : Google Scholar
|
|
6
|
He F, Zhang W, Shen Y, Yu P, Bao Q, Wen J,
Hu C and Qiu S: Effects of resection margins on local recurrence of
osteosarcoma in extremity and pelvis: Systematic review and
meta-analysis. Int J Surg. 36:283–292. 2016. View Article : Google Scholar
|
|
7
|
Marcove RC, Miké V, Hajek JV, Levin AG and
Hutter RV: Osteogenic sarcoma under the age of twenty-one. A review
of one hundred and forty-five operative cases. J Bone Joint Surg
Am. 52:411–423. 1970. View Article : Google Scholar
|
|
8
|
Dahlin DC and Coventry MB: Osteogenic
sarcoma. A study of six hundred cases. J Bone Joint Surg Am.
49:101–110. 1967. View Article : Google Scholar
|
|
9
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar
|
|
10
|
Wang B, Xu M, Zheng K and Yu X: Effect of
unplanned therapy on the prognosis of patients with extremity
osteosarcoma. Sci Rep. 6:387832016. View Article : Google Scholar
|
|
11
|
Liu K, Huang J, Ni J, Song D, Ding M, Wang
J, Huang X and Li W: MALAT1 promotes osteosarcoma development by
regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle.
16:578–587. 2017. View Article : Google Scholar
|
|
12
|
Chen L, Wang Q, Wang GD, Wang HS, Huang Y,
Liu XM and Cai XH: miR-16 inhibits cell proliferation by targeting
IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS
Lett. 587:1366–1372. 2013. View Article : Google Scholar
|
|
13
|
Carninci P, Kasukawa T, Katayama S, Gough
J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, et al:
The transcriptional landscape of the mammalian genome. Science.
309:1559–1563. 2005. View Article : Google Scholar
|
|
14
|
Baltimore D: Our genome unveiled. Nature.
409:814–816. 2001. View
Article : Google Scholar
|
|
15
|
Mattick JS: The genetic signatures of
noncoding RNAs. PLoS Genet. 5:e10004592009. View Article : Google Scholar
|
|
16
|
Kour S and Rath PC: Long noncoding RNAs in
aging and age-related diseases. Ageing Res Rev. 26:1–21. 2016.
View Article : Google Scholar
|
|
17
|
Ji Q, Xu X, Song Q, Xu Y, Tai Y, Goodman
SB, Bi W, Xu M, Jiao S, Maloney WJ and Wang Y: miR-223-3p inhibits
human osteosarcoma metastasis and progression by directly targeting
CDH6. Mol Ther. 26:1299–1312. 2018. View Article : Google Scholar
|
|
18
|
Andersen GB, Knudsen A, Hager H, Hansen LL
and Tost J: miRNA profiling identifies deregulated miRNAs
associated with osteosarcoma development and time to metastasis in
two large cohorts. Mol Oncol. 12:114–131. 2018. View Article : Google Scholar
|
|
19
|
ENCODE Project Consortium; Birney E,
Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH,
Weng Z, Snyder M, Dermitzakis ET, et al: Identification and
analysis of functional elements in 1% of the human genome by the
ENCODE pilot project. Nature. 447:799–816. 2007. View Article : Google Scholar
|
|
20
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar
|
|
21
|
Evans JR, Feng FY and Chinnaiyan AM: The
bright side of dark matter: lncRNAs in cancer. J Clin Invest.
126:2775–2782. 2016. View
Article : Google Scholar
|
|
22
|
Lin C and Yang L: Long noncoding RNA in
cancer: Wiring signaling circuitry. Trends Cell Biol. 28:287–301.
2018. View Article : Google Scholar
|
|
23
|
Barrett SP and Salzman J: Circular RNAs:
Analysis, expression and potential functions. Development.
143:1838–1847. 2016. View Article : Google Scholar
|
|
24
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811.
1998. View Article : Google Scholar
|
|
25
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar
|
|
26
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar
|
|
27
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar
|
|
28
|
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J,
Lee J, Provost P, Rådmark O, Kim S and Kim VN: The nuclear RNase
III Drosha initiates microRNA processing. Nature. 425:415–419.
2003. View Article : Google Scholar
|
|
29
|
Foulkes WD, Priest JR and Duchaine TF:
DICER1: Mutations, microRNAs and mechanisms. Nat Rev Cancer.
14:662–672. 2014. View
Article : Google Scholar
|
|
30
|
Stappert L, Roese-Koerner B and Brüstle O:
The role of microRNAs in human neural stem cells, neuronal
differentiation and subtype specification. Cell Tissue Res.
359:47–64. 2015. View Article : Google Scholar
|
|
31
|
Bottai G, Pasculli B, Calin GA and
Santarpia L: Targeting the microRNA-regulating DNA damage/repair
pathways in cancer. Expert Opin Biol Ther. 14:1667–1683. 2014.
View Article : Google Scholar
|
|
32
|
Adams BD, Kasinski AL and Slack FJ:
Aberrant regulation and function of microRNAs in cancer. Curr Biol.
24:R762–R776. 2014. View Article : Google Scholar
|
|
33
|
Huntzinger E and Izaurralde E: Gene
silencing by microRNAs: Contributions of translational repression
and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar
|
|
34
|
Ell B and Kang Y: MicroRNAs as regulators
of bone homeostasis and bone metastasis. Bonekey Rep. 3:5492014.
View Article : Google Scholar
|
|
35
|
Nugent M: MicroRNA function and
dysregulation in bone tumors: The evidence to date. Cancer Manag
Res. 6:15–25. 2014. View Article : Google Scholar
|
|
36
|
Liu W, Jiang D, Gong F, Huang Y, Luo Y,
Rong Y, Wang J, Ge X, Ji C, Fan J and Cai W: miR-210-5p promotes
epithelial-mesenchymal transition by inhibiting PIK3R5 thereby
activating oncogenic autophagy in osteosarcoma cells. Cell Death
Dis. 11:932020. View Article : Google Scholar
|
|
37
|
Luo Y, Liu W, Tang P, Jiang D, Gu C, Huang
Y, Gong F, Rong Y, Qian D, Chen J, et al: miR-624-5p promoted
tumorigenesis and metastasis by suppressing hippo signaling through
targeting PTPRB in osteosarcoma cells. J Exp Clin Cancer Res.
38:4882019. View Article : Google Scholar
|
|
38
|
He M, Shen P, Qiu C and Wang J: miR-627-3p
inhibits osteosarcoma cell proliferation and metastasis by
targeting PTN. Aging (Albany NY). 11:5744–5756. 2019. View Article : Google Scholar
|
|
39
|
Duan Z, Gao Y, Shen J, Choy E, Cote G,
Harmon D, Bernstein K, Lozano-Calderon S, Mankin H and Hornicek FJ:
miR-15b modulates multidrug resistance in human osteosarcoma in
vitro and in vivo. Mol Oncol. 11:151–166. 2017. View Article : Google Scholar
|
|
40
|
Xu M, Jin H, Xu CX, Sun B, Mao Z, Bi WZ
and Wang Y: miR-382 inhibits tumor growth and enhance
chemosensitivity in osteosarcoma. Oncotarget. 5:9472–9483. 2014.
View Article : Google Scholar
|
|
41
|
Wu P, Liang J, Yu F, Zhou Z, Tang J and Li
K: miR-145 promotes osteosarcoma growth by reducing expression of
the transcription factor friend leukemia virus integration 1.
Oncotarget. 7:42241–42251. 2016. View Article : Google Scholar
|
|
42
|
Hirahata M, Osaki M, Kanda Y, Sugimoto Y,
Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Kawai A, Ito H, et
al: PAI-1, a target gene of miR-143, regulates invasion and
metastasis by upregulating MMP-13 expression of human osteosarcoma.
Cancer Med. 5:892–902. 2016. View Article : Google Scholar
|
|
43
|
Lu J, Song G, Tang Q, Yin J, Zou C, Zhao
Z, Xie X, Xu H, Huang G, Wang J, et al: MiR-26a inhibits stem
cell-like phenotype and tumor growth of osteosarcoma by targeting
Jagged1. Oncogene. 36:231–241. 2017. View Article : Google Scholar
|
|
44
|
Zhu K, Liu L, Zhang J, Wang Y, Liang H,
Fan G, Jiang Z, Zhang CY, Chen X and Zhou G: MiR-29b suppresses the
proliferation and migration of osteosarcoma cells by targeting
CDK6. Protein Cell. 7:434–444. 2016. View Article : Google Scholar
|
|
45
|
Jin H and Wang W: MicroRNA-539 suppresses
osteosarcoma cell invasion and migration in vitro and targeting
matrix metallopeptidase-8. Int J Clin Exp Pathol. 8:8075–8082.
2015.
|
|
46
|
Xu B, Xia H, Cao J, Wang Z, Yang Y and Lin
Y: MicroRNA-21 inhibits the apoptosis of osteosarcoma cell line
SAOS-2 via targeting caspase 8. Oncol Res. 25:1161–1168. 2017.
View Article : Google Scholar
|
|
47
|
Zhang H, Guo X, Feng X, Wang T, Hu Z, Que
X, Tian Q, Zhu T, Guo G, Huang W and Li X: MiRNA-543 promotes
osteosarcoma cell proliferation and glycolysis by partially
suppressing PRMT9 and stabilizing HIF-1α protein. Oncotarget.
8:2342–2355. 2017. View Article : Google Scholar
|
|
48
|
Salah Z, Arafeh R, Maximov V, Galasso M,
Khawaled S, Abou-Sharieha S, Volinia S, Jones KB, Croce CM and
Aqeilan RI: miR-27a and miR-27a* contribute to metastatic
properties of osteosarcoma cells. Oncotarget. 6:4920–4935. 2015.
View Article : Google Scholar
|
|
49
|
Huang YZ, Zhang J, Shao HY, Chen JP and
Zhao HY: MicroRNA-191 promotes osteosarcoma cells proliferation by
targeting checkpoint kinase 2. Tumour Biol. 36:6095–6101. 2015.
View Article : Google Scholar
|
|
50
|
Wang C, Ba X, Guo Y, Sun D, Jiang H, Li W,
Huang Z, Zhou G, Wu S, Zhang J and Chen J: MicroRNA-199a-5p
promotes tumour growth by dual-targeting PIAS3 and p27 in human
osteosarcoma. Sci Rep. 7:414562017. View Article : Google Scholar
|
|
51
|
Zhu SW, Li JP, Ma XL, Ma JX, Yang Y, Chen
Y and Liu W: miR-9 modulates osteosarcoma cell growth by targeting
the GCIP tumor suppressor. Asian Pac J Cancer Prev. 16:4509–4513.
2015. View Article : Google Scholar
|
|
52
|
Zhou S, Wang B, Hu J, Zhou Y, Jiang M, Wu
M, Qin L and Yang X: miR-421 is a diagnostic and prognostic marker
in patients with osteosarcoma. Tumour Biol. 37:9001–9007. 2016.
View Article : Google Scholar
|
|
53
|
Yuan J, Chen L, Chen X, Sun W and Zhou X:
Identification of serum microRNA-21 as a biomarker for
chemosensitivity and prognosis in human osteosarcoma. J Int Med
Res. 40:2090–2097. 2012. View Article : Google Scholar
|
|
54
|
Yao ZS, Li C, Liang D, Jiang XB, Tang JJ,
Ye LQ, Yuan K, Ren H, Yang ZD, Jin DX, et al: Diagnostic and
prognostic implications of serum miR-101 in osteosarcoma. Cancer
Biomark. 22:127–133. 2018. View Article : Google Scholar
|
|
55
|
Lian F, Cui Y, Zhou C, Gao K and Wu L:
Identification of a plasma four-microRNA panel as potential
noninvasive biomarker for osteosarcoma. PLoS One. 10:e01214992015.
View Article : Google Scholar
|
|
56
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar
|
|
57
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar
|
|
58
|
Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu
JX, DeVere White RW, Wun T, Lara PN, Lam KS, et al: Co-targeting of
DNA, RNA, and protein molecules provides optimal outcomes for
treating osteosarcoma and pulmonary metastasis in spontaneous and
experimental metastasis mouse models. Oncotarget. 8:30742–30755.
2017. View Article : Google Scholar
|
|
59
|
Derrien T, Johnson R, Bussotti G, Tanzer
A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG,
et al: The GENCODE v7 catalog of human long noncoding RNAs:
Analysis of their gene structure, evolution, and expression. Genome
Res. 22:1775–1789. 2012. View Article : Google Scholar
|
|
60
|
Cabili MN, Trapnell C, Goff L, Koziol M,
Tazon-Vega B, Regev A and Rinn JL: Integrative annotation of human
large intergenic noncoding RNAs reveals global properties and
specific subclasses. Genes Dev. 25:1915–1927. 2011. View Article : Google Scholar
|
|
61
|
Zhang K, Shi ZM, Chang YN, Hu ZM, Qi HX
and Hong W: The ways of action of long non-coding RNAs in cytoplasm
and nucleus. Gene. 547:1–9. 2014. View Article : Google Scholar
|
|
62
|
Chen LL: Linking long noncoding RNA
localization and function. Trends Biochem Sci. 41:761–772. 2016.
View Article : Google Scholar
|
|
63
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar
|
|
64
|
Sun J, Lin Y and Wu J: Long non-coding RNA
expression profiling of mouse testis during postnatal development.
PLoS One. 8:e757502013. View Article : Google Scholar
|
|
65
|
Ríos-Barrera LD, Gutiérrez-Pérez I,
Domínguez M and Riesgo-Escovar JR: acal is a long non-coding RNA in
JNK signaling in epithelial shape changes during drosophila dorsal
closure. PLoS Genet. 11:e10049272015. View Article : Google Scholar
|
|
66
|
Tao F, Tian X, Ruan S, Shen M and Zhang Z:
miR-211 sponges lncRNA MALAT1 to suppress tumor growth and
progression through inhibiting PHF19 in ovarian carcinoma. FASEB J.
fj201800495RR2018.Online ahead of print.
|
|
67
|
Schaukowitch K and Kim TK: Emerging
epigenetic mechanisms of long non-coding RNAs. Neuroscience.
264:25–38. 2014. View Article : Google Scholar
|
|
68
|
Wang Y, Zeng X, Wang N, Zhao W, Zhang X,
Teng S, Zhang Y and Lu Z: Long noncoding RNA DANCR, working as a
competitive endogenous RNA, promotes ROCK1-mediated proliferation
and metastasis via decoying of miR-335-5p and miR-1972 in
osteosarcoma. Mol Cancer. 17:892018. View Article : Google Scholar
|
|
69
|
Wang X, Peng L, Gong X, Zhang X and Sun R:
LncRNA HIF1A-AS2 promotes osteosarcoma progression by acting as a
sponge of miR-129-5p. Aging (Albany NY). 11:11803–11813. 2019.
View Article : Google Scholar
|
|
70
|
Fu D, Lu C, Qu X, Li P, Chen K, Shan L and
Zhu X: LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and
drug resistance via the miR-134-5p/MBTD1 axis. Aging (Albany NY).
11:8374–8385. 2019. View Article : Google Scholar
|
|
71
|
Li S, Liu F, Pei Y, Wang W, Zheng K and
Zhang X: Long noncoding RNA TTN-AS1 enhances the malignant
characteristics of osteosarcoma by acting as a competing endogenous
RNA on microRNA-376a thereby upregulating dickkopf-1. Aging (Albany
NY). 11:7678–7693. 2019. View Article : Google Scholar
|
|
72
|
Ba Z, Gu L, Hao S, Wang X, Cheng Z and Nie
G: Downregulation of lncRNA CASC2 facilitates osteosarcoma growth
and invasion through miR-181a. Cell Prolif. 51:e124092018.
View Article : Google Scholar
|
|
73
|
Wang Z, Liu Z and Wu S: Long non-coding
RNA CTA sensitizes osteosarcoma cells to doxorubicin through
inhibition of autophagy. Oncotarget. 8:31465–31477. 2017.
View Article : Google Scholar
|
|
74
|
Ye K, Wang S, Zhang H, Han H, Ma B and Nan
W: Long noncoding RNA GAS5 suppresses cell growth and
epithelial-mesenchymal transition in osteosarcoma by regulating the
miR-221/ARHI pathway. J Cell Biochem. 118:4772–4781. 2017.
View Article : Google Scholar
|
|
75
|
Kun-Peng Z, Xiao-Long M and Chun-Lin Z:
LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma
cells through down-regulating ABCB1 and ABCC1. Oncotarget.
8:71881–71893. 2017. View Article : Google Scholar
|
|
76
|
Zhao J and Ma ST: Downregulation of lncRNA
H19 inhibits migration and invasion of human osteosarcoma through
the NF-κB pathway. Mol Med Rep. 17:7388–7394. 2018.
|
|
77
|
Zhou S, Yu L, Xiong M and Dai G: LncRNA
SNHG12 promotes tumorigenesis and metastasis in osteosarcoma by
upregulating Notch2 by sponging miR-195-5p. Biochem Biophys Res
Commun. 495:1822–1832. 2018. View Article : Google Scholar
|
|
78
|
Ji S, Wang S, Zhao X and Lv L: Long
noncoding RNA NEAT1 regulates the development of osteosarcoma
through sponging miR-34a-5p to mediate HOXA13 expression as a
competitive endogenous RNA. Mol Genet Genomic Med. 7:e6732019.
View Article : Google Scholar
|
|
79
|
Guan H, Shang G, Cui Y, Liu J, Sun X, Cao
W, Wang Y and Li Y: Long noncoding RNA APTR contributes to
osteosarcoma progression through repression of miR-132-3p and
upregulation of yes-associated protein 1. J Cell Physiol.
234:8998–9007. 2019. View Article : Google Scholar
|
|
80
|
Bielack S, Carrle D and Casali PG; ESMO
Guidelines Working Group: Osteosarcoma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
20(Suppl): S137–S139. 2009. View Article : Google Scholar
|
|
81
|
Dong Y, Liang G, Yuan B, Yang C, Gao R and
Zhou X: MALAT1 promotes the proliferation and metastasis of
osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol.
36:1477–1486. 2015. View Article : Google Scholar
|
|
82
|
Ma B, Li M, Zhang L, Huang M, Lei JB, Fu
GH, Liu CX, Lai QW, Chen QQ and Wang YL: Upregulation of long
non-coding RNA TUG1 correlates with poor prognosis and disease
status in osteosarcoma. Tumour Biol. 37:4445–4455. 2016. View Article : Google Scholar
|
|
83
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar
|
|
84
|
Nigro JM, Cho KR, Fearon ER, Kern SE,
Ruppert JM, Oliner JD, Kinzler KW and Vogelstein B: Scrambled
exons. Cell. 64:607–613. 1991. View Article : Google Scholar
|
|
85
|
Jeck WR and Sharpless NE: Detecting and
characterizing circular RNAs. Nat Biotechnol. 32:453–461. 2014.
View Article : Google Scholar
|
|
86
|
Lei K, Bai H, Wei Z, Xie C, Wang J, Li J
and Chen Q: The mechanism and function of circular RNAs in human
diseases. Exp Cell Res. 368:147–158. 2018. View Article : Google Scholar
|
|
87
|
Chen LL and Yang L: Regulation of circRNA
biogenesis. RNA Biol. 12:381–388. 2015. View Article : Google Scholar
|
|
88
|
Memczak S, Jens M, Elefsinioti A, Torti F,
Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer
M, et al: Circular RNAs are a large class of animal RNAs with
regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar
|
|
89
|
de Almeida RA, Fraczek MG, Parker S,
Delneri D and O'Keefe RT: Non-coding RNAs and disease: The
classical ncRNAs make a comeback. Biochem Soc Trans. 44:1073–1078.
2016. View Article : Google Scholar
|
|
90
|
Han B, Chao J and Yao H: Circular RNA and
its mechanisms in disease: From the bench to the clinic. Pharmacol
Ther. 187:31–44. 2018. View Article : Google Scholar
|
|
91
|
Wu Y, Xie Z, Chen J, Chen J, Ni W, Ma Y,
Huang K, Wang G, Wang J, Ma J, et al: Circular RNA circTADA2A
promotes osteosarcoma progression and metastasis by sponging
miR-203a-3p and regulating CREB3 expression. Mol Cancer. 18:732019.
View Article : Google Scholar
|
|
92
|
Song YZ and Li JF: Circular RNA
hsa_circ_0001564 regulates osteosarcoma proliferation and apoptosis
by acting miRNA sponge. Biochem Biophys Res Commun. 495:2369–2375.
2018. View Article : Google Scholar
|
|
93
|
Kun-Peng Z, Xiao-Long M and Chun-Lin Z:
Overexpressed circPVT1, a potential new circular RNA biomarker,
contributes to doxorubicin and cisplatin resistance of osteosarcoma
cells by regulating ABCB1. Int J Biol Sci. 14:321–330. 2018.
View Article : Google Scholar
|
|
94
|
Huang L, Chen M, Pan J and Yu W: Circular
RNA circNASP modulates the malignant behaviors in osteosarcoma via
miR-1253/FOXF1 pathway. Biochem Biophys Res Commun. 500:511–517.
2018. View Article : Google Scholar
|
|
95
|
Wu Z, Shi W and Jiang C: Overexpressing
circular RNA hsa_ circ_0002052 impairs osteosarcoma progression via
inhibiting Wnt/β-catenin pathway by regulating miR-1205/APC2 axis.
Biochem Biophys Res Commun. 502:465–471. 2018. View Article : Google Scholar
|
|
96
|
Ren C, Liu J, Zheng B, Yan P, Sun Y and
Yue B: The circular RNA circ-ITCH acts as a tumour suppressor in
osteosarcoma via regulating miR-22. Artif Cells Nanomed Biotechnol.
47:3359–3367. 2019. View Article : Google Scholar
|
|
97
|
Li H, Lan M, Liao X, Tang Z and Yang C:
Circular RNA cir-ITCH promotes osteosarcoma migration and invasion
through cir-ITCH/miR-7/EGFR pathway. Technol Cancer Res Treat.
19:15330338198987282020.
|
|
98
|
Xiao-Long M, Kun-Peng Z and Chun-Lin Z:
Circular RNA circ_HIPK3 is down-regulated and suppresses cell
proliferation, migration and invasion in osteosarcoma. J Cancer.
9:1856–1862. 2018. View Article : Google Scholar
|
|
99
|
Jin Y, Li L, Zhu T and Liu G: Circular RNA
circ_0102049 promotes cell progression as ceRNA to target MDM2 via
sponging miR-1304-5p in osteosarcoma. Pathol Res Pract.
215:1526882019. View Article : Google Scholar
|
|
100
|
Li L, Guo L, Yin G, Yu G, Zhao Y and Pan
Y: Upregulation of circular RNA circ_0001721 predicts unfavorable
prognosis in osteosarcoma and facilitates cell progression via
sponging miR-569 and miR-599. Biomed Pharmacother. 109:226–232.
2019. View Article : Google Scholar
|
|
101
|
Li JF and Song YZ: Circular RNA GLI2
promotes osteosarcoma cell proliferation, migration, and invasion
by targeting miR-125b-5p. Tumour Biol. 39:10104283177099912017.
View Article : Google Scholar
|
|
102
|
Li S, Pei Y, Wang W, Liu F, Zheng K and
Zhang X: Circular RNA 0001785 regulates the pathogenesis of
osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2.
Cell Cycle. 18:1281–1291. 2019. View Article : Google Scholar
|
|
103
|
Cao J and Liu XS: Circular RNA 0060428
sponges miR-375 to promote osteosarcoma cell proliferation by
upregulating the expression of RPBJ. Gene. 740:1445202020.
View Article : Google Scholar
|
|
104
|
Li S, Sun X, Miao S, Lu T, Wang Y, Liu J
and Jiao W: hsa_circ_0000729, a potential prognostic biomarker in
lung adenocarcinoma. Thorac Cancer. 9:924–930. 2018. View Article : Google Scholar
|
|
105
|
Li XM, Ge HM, Yao J, Zhou YF, Yao MD, Liu
C, Hu HT, Zhu YX, Shan K, Yan B and Jiang Q: Genome-wide
identification of circular RNAs as a novel class of putative
biomarkers for an ocular surface disease. Cell Physiol Biochem.
47:1630–1642. 2018. View Article : Google Scholar
|
|
106
|
Zhang H, Wang G, Ding C, Liu P, Wang R,
Ding W, Tong D, Wu D, Li C, Wei Q, et al: Increased circular RNA
UBAP2 acts as a sponge of miR-143 to promote osteosarcoma
progression. Oncotarget. 8:61687–61697. 2017. View Article : Google Scholar
|
|
107
|
Liu X, Abraham JM, Cheng Y, Wang Z, Wang
Z, Zhang G, Ashktorab H, Smoot DT, Cole RN, Boronina TN, et al:
Synthetic circular RNA functions as a miR-21 sponge to suppress
gastric carcinoma cell proliferation. Mol Ther Nucleic Acids.
13:312–321. 2018. View Article : Google Scholar
|
|
108
|
Xu S, Gong Y, Yin Y, Xing H and Zhang N:
The multiple function of long noncoding RNAs in osteosarcoma
progression, drug resistance and prognosis. Biomed Pharmacother.
127:1101412020. View Article : Google Scholar
|
|
109
|
Yin F, Wang Z, Jiang Y, Zhang T, Wang Z,
Hua Y, Song Z, Liu J, Xu W, Xu J, et al: Reduction-responsive
polypeptide nanomedicines significantly inhibit progression of
orthotopic osteosarcoma. Nanomedicine. 23:1020852020. View Article : Google Scholar
|
|
110
|
Matsui M and Corey DR: Non-coding RNAs as
drug targets. Nat Rev Drug Discov. 16:167–179. 2017. View Article : Google Scholar
|
|
111
|
Li Z and Rana TM: Therapeutic targeting of
microRNAs: Current status and future challenges. Nat Rev Drug
Discov. 13:622–638. 2014. View Article : Google Scholar
|
|
112
|
Wang WT, Han C, Sun YM, Chen TQ and Chen
YQ: Noncoding RNAs in cancer therapy resistance and targeted drug
development. J Hematol Oncol. 12:552019. View Article : Google Scholar
|
|
113
|
Huang KW, Lai YT, Chern GJ, Huang SF, Tsai
CL, Sung YC, Chiang CC, Hwang PB, Ho TL, Huang RL, et al: Galactose
derivative-modified nanoparticles for efficient siRNA delivery to
hepatocellular carcinoma. Biomacromolecules. 19:2330–2339. 2018.
View Article : Google Scholar
|
|
114
|
Nair JK, Willoughby JL, Chan A, Charisse
K, Alam MR, Wang Q, Hoekstra M, Kandasamy P, Kel'in AV, Milstein S,
et al: Multivalent N-acetylgalactosamine-conjugated siRNA localizes
in hepatocytes and elicits robust RNAi-mediated gene silencing. J
Am Chem Soc. 136:16958–16961. 2014. View Article : Google Scholar
|
|
115
|
Wen JJ, Ma YD, Yang GS and Wang GM:
Analysis of circulating long non-coding RNA UCA1 as potential
biomarkers for diagnosis and prognosis of osteosarcoma. Eur Rev Med
Pharmacol Sci. 21:498–503. 2017.
|
|
116
|
Huang JZ, Chen M, Chen D, Gao XC, Zhu S,
Huang H, Hu M, Zhu H and Yan GR: A peptide encoded by a putative
lncRNA HOXB-AS3 suppresses colon cancer growth. Mol Cell.
68:171–184.e6. 2017. View Article : Google Scholar
|
|
117
|
Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao
F, Huang N, Yang X, Zhao K, Zhou H, et al: Novel role of FBXW7
circular RNA in repressing glioma tumorigenesis. J Natl Cancer
Inst. 110:3042018. View Article : Google Scholar
|
|
118
|
Ribatti D: The concept of immune
surveillance against tumors. The first theories Oncotarget.
8:7175–7180. 2017. View Article : Google Scholar
|
|
119
|
Ji X, Wang E and Tian F: MicroRNA-140
suppresses osteosarcoma tumor growth by enhancing anti-tumor immune
response and blocking mTOR signaling. Biochem Biophys Res Commun.
495:1342–1348. 2018. View Article : Google Scholar
|
|
120
|
Li S, Li X, Xue W, Zhang L, Yang LZ, Cao
SM, Lei YN, Liu CX, Guo SK, Shan L, et al: Screening for functional
circular RNAs using the CRISPR-Cas13 system. Nat Methods. 18:51–59.
2021. View Article : Google Scholar
|
